Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 148
- Registration Number
- NCT01724866
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Los Angeles, California, United States
🇺🇸Beaver Medical Group, Highland, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- Target Recruit Count
- 24
- Registration Number
- NCT01637493
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT01624805
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 25
- Registration Number
- NCT01594918
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2012-02-29
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 34
- Registration Number
- NCT01541072
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷CHU Clermont-Ferrand, Hôpital d'Estaing, Clermont-Ferrand, France
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Emory University
- Target Recruit Count
- 7
- Registration Number
- NCT01498588
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Anne Beaven, MD
- Target Recruit Count
- 33
- Registration Number
- NCT01491841
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Study of LY2523355 in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT01416389
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
Pazopanib, Docetaxel, Prednisone Prostate
- Conditions
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Daniel George, MD
- Target Recruit Count
- 36
- Registration Number
- NCT01385228
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Michaela Liedtke
- Target Recruit Count
- 14
- Registration Number
- NCT01355705
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.